Abbott wins FDA nod for Advisor HD Gridcardiac mapping cath

Abbott (NYSE:ABT) said today it won FDA clearance for is Advisor HD Grid mapping sensor enabled catheter designed for creating highly detailed maps of the heart.

The newly cleared mapping catheter builds on the Abbott Park, Ill.-based company’s previous designs and and is intended to improve cardiac ablation procedures by providing an inside view of the heart for more accurate identification of the cardiac anatomy.

The Advisor HD Grid catheter is designed to capture data including the direction and speed of cardiac signals, and allows for the creation of high-density maps of cardiac tissue for more optimal treatment regimens, Abbott said.

The catheter’s sensor enabled technology can also improve accuracy of the cardiac image when paired with the company’s EnSite Precision cardiac mapping system, Abbott said.

“At the University of Chicago Medicine, we are passionate about understanding and redefining arrhythmia mechanisms with higher resolution cardiac mapping. Abbott’s Advisor HD Grid represents an important step in the development of next generation mapping catheters. With a flexible and soft design using magnetic sensor technology, the catheter helps capture signals previous catheters may have missed to support the creation of highly detailed 3D maps of the heart. Innovation within the field of electrophysiology continues to evolve toward improving our ability to visualize arrhythmias in much greater detail, and we are confident that patient outcomes will improve as a result,” Dr. Roderick Tung if the University of Chicago Hospitals said in a prepared statement.

The Advisor HD Grid mapping catheter won CE Mark approval last December, the company said.

“The goal in developing the Advisor HD Grid mapping catheter, sensor enabled was to provide physicians with an innovative solution to quickly and accurately map complex arrhythmias in patients,” Abbott electrophysiology biz medical director Dr. Srijoy Mahapatra said in a press release.

Last month, a post-approval registry study of Abbott’s MitraClip mitral valve repair device showed positive results at one year, according to late-breaking results presented at the annual meeting of the Society for Cardiovascular Angiography & Interventions in San Diego.

The post Abbott wins FDA nod for Advisor HD Gridcardiac mapping cath appeared first on MassDevice.

from MassDevice https://ift.tt/2Ia7UoJ